Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection

This study is testing whether mesenchymal stromal cells (MSCs) — a type of stem cell with anti-inflammatory properties — can help treat severe COVID-19 pneumonia. When COVID-19 causes an extreme immune overreaction (sometimes called a cytokine storm), the lungs become severely inflamed. MSCs may help calm this response and support recovery. The trial enrolls adults with severe COVID-19 who require oxygen or are on mechanical ventilation, and compares those who receive MSC therapy to those who receive standard care alone. You may be eligible if: - You are between 18 and 70 years of age - You have confirmed COVID-19 pneumonia shown on CT scan and/or positive PCR/serology - You require supplemental oxygen (oxygen saturation ≤93% on room air) - You are in standard care or an ICU, or on a mechanical ventilator for up to 14 days with ongoing high inflammation You may NOT be eligible if: - You are pregnant - You are on extracorporeal membrane oxygenation (ECMO) - Your life expectancy is less than 24 hours - You have an active secondary infection or active cancer (within 2 years) - You are enrolled in another clinical trial Talk to your doctor to see if this trial is right for you.